Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
Valid factors to evaluate the prognosis of triple-negative breast cancer (TNBC) with residual disease after neoadjuvant chemotherapy (NAC) are still lacking. We performed this study to explore prognostic factors focusing on genetic alterations and clinicopathology features in non- pathologic complet...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/13/2/190 |
| _version_ | 1797619947914919936 |
|---|---|
| author | Zhijun Li Yiqun Han Jiayu Wang Binghe Xu |
| author_facet | Zhijun Li Yiqun Han Jiayu Wang Binghe Xu |
| author_sort | Zhijun Li |
| collection | DOAJ |
| description | Valid factors to evaluate the prognosis of triple-negative breast cancer (TNBC) with residual disease after neoadjuvant chemotherapy (NAC) are still lacking. We performed this study to explore prognostic factors focusing on genetic alterations and clinicopathology features in non- pathologic complete response (pCR) TNBC patients. Patients initially diagnosed with early-stage TNBC, treated with NAC, and who had residual disease after primary tumor surgery at the China National Cancer Center during 2016 and 2020 were enrolled. Genomic analyses were performed by targeted sequencing for each tumor sample. Univariable and multivariable analyses were conducted to screen prognostic factors for the survival of patients. Fifty-seven patients were included in our study. Genomic analyses showed that <i>TP53</i> (41/57, 72%), <i>PIK3CA</i> (12/57, 21%), and <i>MET</i> (7/57, 12%), and <i>PTEN</i> (7/57, 12%) alternations commonly occurred. The clinical TNM (cTNM) stage and <i>PIK3CA</i> status were independent prognostic factors of disease-free survival (DFS) (<i>p</i> < 0.001, <i>p</i> = 0.03). A prognostic stratification indicated that patients with clinical stages I &II possessed the best DFS, followed by those with clinical stage III & wild-type <i>PIK3CA</i>. In contrast, patients with clinical stage III & the <i>PIK3CA</i> mutation had the worst DFS. In TNBC patients with residual disease after NAC, prognostic stratification for DFS was observed by combining the cTNM stage and <i>PIK3CA</i> status. |
| first_indexed | 2024-03-11T08:34:16Z |
| format | Article |
| id | doaj.art-1e5fabeb14604acc9e5149d5a3c975a8 |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-11T08:34:16Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-1e5fabeb14604acc9e5149d5a3c975a82023-11-16T21:31:59ZengMDPI AGJournal of Personalized Medicine2075-44262023-01-0113219010.3390/jpm13020190Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant ChemotherapyZhijun Li0Yiqun Han1Jiayu Wang2Binghe Xu3Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaValid factors to evaluate the prognosis of triple-negative breast cancer (TNBC) with residual disease after neoadjuvant chemotherapy (NAC) are still lacking. We performed this study to explore prognostic factors focusing on genetic alterations and clinicopathology features in non- pathologic complete response (pCR) TNBC patients. Patients initially diagnosed with early-stage TNBC, treated with NAC, and who had residual disease after primary tumor surgery at the China National Cancer Center during 2016 and 2020 were enrolled. Genomic analyses were performed by targeted sequencing for each tumor sample. Univariable and multivariable analyses were conducted to screen prognostic factors for the survival of patients. Fifty-seven patients were included in our study. Genomic analyses showed that <i>TP53</i> (41/57, 72%), <i>PIK3CA</i> (12/57, 21%), and <i>MET</i> (7/57, 12%), and <i>PTEN</i> (7/57, 12%) alternations commonly occurred. The clinical TNM (cTNM) stage and <i>PIK3CA</i> status were independent prognostic factors of disease-free survival (DFS) (<i>p</i> < 0.001, <i>p</i> = 0.03). A prognostic stratification indicated that patients with clinical stages I &II possessed the best DFS, followed by those with clinical stage III & wild-type <i>PIK3CA</i>. In contrast, patients with clinical stage III & the <i>PIK3CA</i> mutation had the worst DFS. In TNBC patients with residual disease after NAC, prognostic stratification for DFS was observed by combining the cTNM stage and <i>PIK3CA</i> status.https://www.mdpi.com/2075-4426/13/2/190triple-negative breast neoplasmsnon-pathologic complete response<i>PIK3CA</i>prognosis |
| spellingShingle | Zhijun Li Yiqun Han Jiayu Wang Binghe Xu Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy Journal of Personalized Medicine triple-negative breast neoplasms non-pathologic complete response <i>PIK3CA</i> prognosis |
| title | Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy |
| title_full | Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy |
| title_fullStr | Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy |
| title_full_unstemmed | Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy |
| title_short | Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy |
| title_sort | prognostic factors for triple negative breast cancer with residual disease after neoadjuvant chemotherapy |
| topic | triple-negative breast neoplasms non-pathologic complete response <i>PIK3CA</i> prognosis |
| url | https://www.mdpi.com/2075-4426/13/2/190 |
| work_keys_str_mv | AT zhijunli prognosticfactorsfortriplenegativebreastcancerwithresidualdiseaseafterneoadjuvantchemotherapy AT yiqunhan prognosticfactorsfortriplenegativebreastcancerwithresidualdiseaseafterneoadjuvantchemotherapy AT jiayuwang prognosticfactorsfortriplenegativebreastcancerwithresidualdiseaseafterneoadjuvantchemotherapy AT binghexu prognosticfactorsfortriplenegativebreastcancerwithresidualdiseaseafterneoadjuvantchemotherapy |